DUSA is a Wilmington, Mass-based dermatology company. Its commercial brands include BLU-U and LEVULAN/KERASTICK.
Levulan combination therapy is approved by FDA for treatment of non-hyperkeratotic actinic keratoses. BLU-U treatment has been approved by FDA for the treatment of moderate inflammatory acne vulgaris and general dermatological conditions.
“We believe this transaction brings significant value to DUSA shareholders and are pleased that Sun Pharma recognized the value that has been created,” said Robert Doman, president and CEO of DUSA Pharmaceuticals, in the release. “We are confident that Sun Pharma will build upon the solid foundation our organization has established in the United States dermatology market to further expand access to Levulan for patients with actinic kerotoses.”
Sun Pharmaceutical Industries is headquartered in India.
Related Articles on Company Acquisitions:
Bausch + Lomb to Acquire Ophthalmology Laser Company
Sparton to Acquire Onyx EMS for $43M
Endeavour Capital Acquires Access Scientific
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.